X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DISHMAN PHARMA ALEMBIC PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 22.2 25.1 88.6% View Chart
P/BV x 5.2 3.3 156.7% View Chart
Dividend Yield % 0.6 0.7 97.5%  

Financials

 ALEMBIC PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs645374 172.3%   
Low Rs470129 364.5%   
Sales per share (Unadj.) Rs166.1197.8 84.0%  
Earnings per share (Unadj.) Rs21.921.2 103.3%  
Cash flow per share (Unadj.) Rs27.534.7 79.2%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.70.8 90.3%  
Book value per share (Unadj.) Rs117.8179.9 65.5%  
Shares outstanding (eoy) m188.5280.69 233.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 263.8%   
Avg P/E ratio x25.511.9 214.5%  
P/CF ratio (eoy) x20.37.2 279.8%  
Price / Book Value ratio x4.71.4 338.4%  
Dividend payout %18.39.4 193.7%   
Avg Mkt Cap Rs m105,09020,306 517.5%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m6,2285,355 116.3%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m31,30815,961 196.2%  
Other income Rs m70265 26.5%   
Total revenues Rs m31,37816,226 193.4%   
Gross profit Rs m6,4314,103 156.7%  
Depreciation Rs m1,0551,091 96.7%   
Interest Rs m34944 3.6%   
Profit before tax Rs m5,4132,334 231.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-811 -7,354.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,204624 193.0%   
Profit after tax Rs m4,1281,711 241.3%  
Gross profit margin %20.525.7 79.9%  
Effective tax rate %22.226.7 83.2%   
Net profit margin %13.210.7 123.0%  
BALANCE SHEET DATA
Current assets Rs m18,24711,018 165.6%   
Current liabilities Rs m11,2359,517 118.1%   
Net working cap to sales %22.49.4 238.2%  
Current ratio x1.61.2 140.3%  
Inventory Days Days86110 77.4%  
Debtors Days Days6135 176.1%  
Net fixed assets Rs m20,03516,304 122.9%   
Share capital Rs m377161 233.6%   
"Free" reserves Rs m21,82412,907 169.1%   
Net worth Rs m22,20114,516 152.9%   
Long term debt Rs m5,0004,189 119.3%   
Total assets Rs m39,41129,805 132.2%  
Interest coverage x160.23.5 4,615.2%   
Debt to equity ratio x0.20.3 78.0%  
Sales to assets ratio x0.80.5 148.3%   
Return on assets %10.68.9 118.5%  
Return on equity %18.611.8 157.7%  
Return on capital %19.717.5 112.5%  
Exports to sales %46.424.8 187.3%   
Imports to sales %10.53.7 281.1%   
Exports (fob) Rs m14,5353,956 367.4%   
Imports (cif) Rs m3,288596 551.5%   
Fx inflow Rs m14,7224,952 297.3%   
Fx outflow Rs m7,026697 1,008.3%   
Net fx Rs m7,6964,255 180.9%   
CASH FLOW
From Operations Rs m3,1242,786 112.1%  
From Investments Rs m-8,844-1,529 578.4%  
From Financial Activity Rs m5,026-941 -534.1%  
Net Cashflow Rs m-693316 -219.1%  

Share Holding

Indian Promoters % 74.1 61.4 120.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 3.7 78.4%  
FIIs % 9.1 12.7 71.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 22.1 62.9%  
Shareholders   49,328 46,261 106.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Dec 13, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS